Medicure Inc. · TSXV:MPH

Medicure — Investor Presentation (September 2015)

19 slides from Medicure's investor presentation, Sep 30, 2015

  1. Slide 1: Investor Presentation

    Investor Presentation Albert D. Friesen, PhD Dawson Reimer Chair & CEO President & COO September 30, 2015

  2. Slide 2: Disclaimer

    Disclaimer This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements

  3. Slide 3: Aggrastat Prescribing Information

    Aggrastat Prescribing Information Indication: AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). Dosag

  4. Slide 4: Medicure Inc.

    Medicure Inc. A specialty pharmaceutical company focused on the development and commercialization of therapeutics for the U.S. hospital market. Core Competencies: • Unique, head-office based sales team • One of the only hospital cardiology pharma sales teams in the U.S. 4

  5. Slide 5: Net Revenue Growth: 2012 – 2015 (CDN)

    Net Revenue Growth: 2012 – 2015 (CDN) $18,000,000 $16,000,000 Annualized Projected $14,000,000 2015 $12,000,000 $10,000,000 Actual Q1-Q3 2015 $8,000,000 $6,000,000 $4,000,000 $2,000,000 $0 2012 2013 2014 2015 5

  6. Slide 6: Adjusted EBITDA Growth: 2012 – 2015 (CDN)

    Adjusted EBITDA Growth: 2012 – 2015 (CDN) $6,000,000 Annualized $5,000,000 Projected 2015 $4,000,000 Actual Q1-Q3 $3,000,000 2015 $2,000,000 $1,000,000 $0 2012 2013 2014 2015 -$1,000,000 -$2,000,000 6

  7. Slide 7: Aggrastat: acute cardiovascular hospital product

     Acute cardiovascular hospital product  I.V. platelet inhibitor; binds the GP IIb/IIIa receptor  Indicated for Acute Coronary Syndrome (ACS)  41% reduction in death and MI in high-risk patients*  Oct 2013: FDA Approved High Dose Bolus  Patented until June 2023  Sept 2015: sNDA filed for STEMI

  8. Slide 8: Commercial Product: Aggrastat

    Commercial Product: Aggrastat® United States GP IIb/IIIa Market USD $274.5 million, July 2014 – June 2015  Launched by Merck in 1998  Is the #1 in class ex-USA  U.S. rights acquired by Medicure in 2006  Medicure obtained broader FDA approval in October 2013 * Gross Sales before discounts. Source

  9. Slide 9: Competitive Positioning of Aggrastat

    Competitive Positioning of Aggrastat 9

  10. Slide 10: New US Hospitals Using Aggrastat

    New US Hospitals Using Aggrastat Jan 2012 – Sept 2015 10

  11. Slide 11: Weekly Bag Demand (“Weekly Scripts”)

    Weekly Bag Demand (“Weekly Scripts”) 11

  12. Slide 12: GPI Treatment Costs in the US

    $3,500 GPI Treatment Costs in the US $3,000 Aggrastat: 25 µg/kg bolus + 0.15 µg/kg/min  US healthcare system is $2,500 financially stressed Integrilin: 2x180 µg/kg bolus + 2.0 µg/kg/min $2,000  Integrilin often one of the largest Reopro: 0.25 mg/kg pharmacy line items $3,126.12 bolus + 0.125 µg/kg

  13. Slide 13: Growth & Business Development

    Growth & Business Development • Building a specialty pharmaceutical portfolio focused on the U.S. hospital market • Leveraging our sales infrastructure • Invest in reduced risk - high reward development projects • Maintain focus on profitability 13

  14. Slide 14: Apicore Transaction: July 2014

    Apicore Transaction: July 2014 Fixed Price Option Fixed Price Option Founders 5.3% Minority Equity Shareholder Equity investor Loan + Warrants a private manufacturer of complex active pharmaceutical ingredients (APIs) and developer of generic products (ANDAs) 14

  15. Slide 15: Apicore Background

    Apicore Background Year Revenue (USD) 2012 $5 Million 2013 $10.3 Million 2014 $14.3 Million  API Manufacturer & ANDA Developer Somerset, New Jersey • Complex synthetic chemistry • Early & “first to file” generics • Secure, high quality production  History: • Founded in 2004 (New Jersey) • First FD

  16. Slide 16: Key Financial Info – MPH: TSXV

    Key Financial Info – MPH: TSXV Cap Structure As of September 30, 2015 Basic Total 14,369,875 Fully Diluted Total 16,740,213 Share Price C$3.62 Market Cap C$52.0M  Recent Financial Highlights Q3 • Net Revenue $5.4 M • *Adj.EBITDA $2.0 M  2015 Financial Focus • Strengthen balance sheet with cash flo

  17. Slide 17: Business Vision

    Business Vision Aggrastat Quarterly Net Product Sales  To build a large, stable, (CDN Millions) specialty pharmaceutical company  To further expand Aggrastat revenue  To expand revenue with new commercial products  To diversify company value with new products and Q1 business areas 17

  18. Slide 18: Aggrastat Prescribing Information

    Aggrastat Prescribing Information Indication: AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). Dosag

  19. Slide 19: Thank you.

    Thank you. Contact a Product Specialist Investor Relations 1.800.509.0544 [email protected] 1.888.435.2220 (Ext. 231) For More Information www.medicure.com www.aggrastat.com 19

Medicure — Investor Presentation (September 2015) on 6ix